CN102046621B - 抗病毒盐 - Google Patents

抗病毒盐 Download PDF

Info

Publication number
CN102046621B
CN102046621B CN200980120191.2A CN200980120191A CN102046621B CN 102046621 B CN102046621 B CN 102046621B CN 200980120191 A CN200980120191 A CN 200980120191A CN 102046621 B CN102046621 B CN 102046621B
Authority
CN
China
Prior art keywords
salt
compound
formula
salts
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980120191.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102046621A (zh
Inventor
J·瑞恩
M·A·布特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biota Scientific Management Pty Ltd
Original Assignee
Biota Scientific Management Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Scientific Management Pty Ltd filed Critical Biota Scientific Management Pty Ltd
Publication of CN102046621A publication Critical patent/CN102046621A/zh
Application granted granted Critical
Publication of CN102046621B publication Critical patent/CN102046621B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN200980120191.2A 2008-05-27 2009-05-27 抗病毒盐 Expired - Fee Related CN102046621B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5634108P 2008-05-27 2008-05-27
US61/056,341 2008-05-27
PCT/AU2009/000663 WO2009143571A1 (en) 2008-05-27 2009-05-27 Antiviral salts

Publications (2)

Publication Number Publication Date
CN102046621A CN102046621A (zh) 2011-05-04
CN102046621B true CN102046621B (zh) 2014-11-12

Family

ID=41376478

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980120191.2A Expired - Fee Related CN102046621B (zh) 2008-05-27 2009-05-27 抗病毒盐

Country Status (14)

Country Link
US (2) US8580791B2 (https=)
EP (1) EP2297141B1 (https=)
JP (1) JP5469662B2 (https=)
KR (1) KR20110019759A (https=)
CN (1) CN102046621B (https=)
AU (1) AU2009253738B2 (https=)
BR (1) BRPI0912038A2 (https=)
CA (1) CA2725618C (https=)
CO (1) CO6280534A2 (https=)
EA (1) EA020455B1 (https=)
MX (1) MX2010013019A (https=)
NZ (1) NZ590286A (https=)
WO (1) WO2009143571A1 (https=)
ZA (1) ZA201009284B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ603040A (en) * 2010-04-15 2015-03-27 Biota Scient Management Compound for treatment of respiratory condition or disease
EP2585067B1 (en) 2010-06-25 2017-08-09 Biota Scientific Management Pty Ltd Compound for the treatment of enteroviruses
CN102617462B (zh) * 2012-02-28 2014-02-12 南京大学 特异性抑制肌肉微小核糖核酸的化合物及其合成方法和应用
EA201692549A1 (ru) * 2014-06-20 2017-08-31 Эвайраджен Терепьютикс, Инк. Безводная кристаллическая форма свободного основания 6-{2-[1-(6-метил-3-пиридазинил)-4-пиперидинил]этокси}-3-этокси-1,2-бензизоксазола
US20250281519A1 (en) * 2021-05-05 2025-09-11 Emory University Nucleotide and nucleoside therapeutic compositions, combinations and uses related thereto
WO2024192151A2 (en) * 2023-03-13 2024-09-19 Altesa BioSciences, Inc. Method of dosing vapendavir to treat enterovirus infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114327A (en) * 1997-06-04 2000-09-05 Eli Lilly And Company Anti-viral compounds
CN1292697A (zh) * 1998-05-20 2001-04-25 伊莱利利公司 抗病毒化合物
WO2002050045A1 (en) * 2000-12-18 2002-06-27 Biota Scientific Management Pty Ltd Antiviral agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1170387B (it) 1982-06-07 1987-06-03 Glaxo Group Ltd Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono
GB2162522B (en) 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB9026998D0 (en) 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
US5514778A (en) * 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US5693661A (en) * 1995-06-07 1997-12-02 Eli Lilly And Company Anti-viral compounds
US5545653A (en) * 1995-06-07 1996-08-13 Eli Lilly And Company Anti-viral compounds
US5891874A (en) * 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5821242A (en) * 1996-06-06 1998-10-13 Eli Lilly And Company Anti-viral compounds
AU6031898A (en) * 1997-01-22 1998-08-07 Eli Lilly And Company Anti-viral compounds
US6358971B1 (en) * 1998-05-20 2002-03-19 Eli Lilly And Company Anti-viral compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114327A (en) * 1997-06-04 2000-09-05 Eli Lilly And Company Anti-viral compounds
CN1292697A (zh) * 1998-05-20 2001-04-25 伊莱利利公司 抗病毒化合物
WO2002050045A1 (en) * 2000-12-18 2002-06-27 Biota Scientific Management Pty Ltd Antiviral agents

Also Published As

Publication number Publication date
EP2297141A4 (en) 2012-04-25
JP2011520991A (ja) 2011-07-21
CN102046621A (zh) 2011-05-04
ZA201009284B (en) 2012-06-27
CA2725618C (en) 2016-04-12
AU2009253738A1 (en) 2009-12-03
EA201001835A1 (ru) 2011-06-30
US9206171B2 (en) 2015-12-08
NZ590286A (en) 2011-08-26
EP2297141B1 (en) 2015-10-21
BRPI0912038A2 (pt) 2017-06-20
WO2009143571A1 (en) 2009-12-03
KR20110019759A (ko) 2011-02-28
AU2009253738B2 (en) 2012-12-13
JP5469662B2 (ja) 2014-04-16
EA020455B1 (ru) 2014-11-28
US20140179710A1 (en) 2014-06-26
US20110144118A1 (en) 2011-06-16
CO6280534A2 (es) 2011-05-20
MX2010013019A (es) 2011-03-21
EP2297141A1 (en) 2011-03-23
CA2725618A1 (en) 2009-12-03
US8580791B2 (en) 2013-11-12

Similar Documents

Publication Publication Date Title
TWI786110B (zh) (s)-2-乙基丁基2-(((s)-(((2r,3s,4r,5r) -5-(4-胺基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4-二羥基四氫呋喃-2-基)甲氧基)(苯氧基)磷醯基)胺基)丙酸酯之結晶形式
CN102046621B (zh) 抗病毒盐
JP2023022155A (ja) Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）－２－（７－（４－シクロペンチル－３－（トリフルオロメチル）ベンジルオキシ）－１，２，３，４－テトラヒドロシクロペンタ［ｂ］インドール－３－イル）酢酸（化合物１）の結晶性Ｌ－アルギニン塩
JP6460498B2 (ja) マンギフェリン−６−ｏ−ベルベリン塩、その製造方法および用途
JP2019526605A (ja) 置換２−ｈ−ピラゾール誘導体の結晶形、塩型及びその製造方法
TWI496773B (zh) Ｎ－［２－［［（２，３－二氟苯基）甲基］硫基］－６－｛［（１ｒ，２ｓ）－２，３－二羥基－１－甲基丙基］氧基｝－４－嘧啶基］－１－三亞甲亞胺磺醯胺之新穎結晶型
KR102572035B1 (ko) 무정형 형태의 빌란테롤 트리페나테이트 및 이의 제조방법
CN106995397A (zh) R‑氨磺必利药用盐、制备方法、晶型及其用途
CN116761612A (zh) α-1062葡糖酸盐的固体形式
CN112236413A (zh) 结晶曲尼司特盐及其药物用途
ES2978392T3 (es) Sal de adición del agonista del receptor S1P1 y forma cristalina de la misma, y composición farmacéutica
CN114853762B (zh) 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
CN116041324A (zh) 一种氘代吡唑二氯苯甲酰胺类化合物、药物组合物和用途
WO2018149309A1 (zh) 4-苯基噻唑衍生物的晶型及其制备方法
WO2018036557A1 (zh) 来那度胺的晶型及其制备方法和用途
CN119462561B (zh) 化合物的晶型及其制备方法、原料药、组合物和用途
TWI916636B (zh) 新型冠狀病毒感染症治療用醫藥
JP2026502598A (ja) スピロ化合物の結晶及びその製造方法
CN120383595A (zh) 抑制cdk4/6活性化合物的半l-酒石酸盐一水合物
WO2022144042A1 (zh) Tas-116的晶型及其制备方法、药物组合物和用途
WO2025035486A1 (zh) 一种酪氨酸激酶抑制剂的可药用盐、结晶形式及其制备方法
CN105732642A (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
HK40097916A (zh) α-1062葡糖酸盐的固体形式
CN114539338A (zh) 一种三磷酸腺苷二钠的三水合物晶体及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141112

Termination date: 20180527